Acadia Healthcare Co. (NASDAQ:ACHC) – Research analysts at Cantor Fitzgerald lowered their FY2016 earnings per share (EPS) estimates for Acadia Healthcare in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst J. France now expects that the brokerage will earn $2.23 per share for the year, down from their prior forecast of $2.65. Cantor Fitzgerald also issued estimates for Acadia Healthcare’s FY2017 earnings at $2.65 EPS.
A number of other equities research analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Acadia Healthcare from a “sell” rating to a “hold” rating in a research report on Monday. JPMorgan Chase & Co. reiterated a “hold” rating and set a $61.00 target price on shares of Acadia Healthcare in a research report on Tuesday, September 27th. Leerink Swann reiterated an “outperform” rating and set a $80.00 target price on shares of Acadia Healthcare in a research report on Monday, September 26th. Robert W. Baird dropped their target price on shares of Acadia Healthcare from $67.00 to $66.00 and set an “outperform” rating for the company in a research report on Thursday, September 15th. Finally, RBC Capital Markets reiterated an “outperform” rating and set a $78.00 target price (down previously from $86.00) on shares of Acadia Healthcare in a research report on Monday, August 1st. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Acadia Healthcare has an average rating of “Buy” and an average price target of $77.21.
Shares of Acadia Healthcare (NASDAQ:ACHC) opened at 47.76 on Thursday. The company has a 50 day moving average of $50.47 and a 200-day moving average of $55.04. The company has a market capitalization of $4.17 billion, a P/E ratio of 25.51 and a beta of 0.86. Acadia Healthcare has a 12-month low of $46.99 and a 12-month high of $74.77.
Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Friday, July 29th. The company reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. Acadia Healthcare had a net margin of 6.44% and a return on equity of 9.35%. The business had revenue of $756.50 million for the quarter, compared to the consensus estimate of $752.57 million. During the same period in the previous year, the firm earned $0.57 EPS. The business’s revenue for the quarter was up 66.8% on a year-over-year basis.
In related news, CFO David M. Duckworth sold 16,670 shares of Acadia Healthcare stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $54.33, for a total transaction of $905,681.10. Following the transaction, the chief financial officer now owns 11,688 shares of the company’s stock, valued at approximately $635,009.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Waud Capital Partners Iii, L.L sold 457,443 shares of Acadia Healthcare stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $48.39, for a total transaction of $22,135,666.77. The disclosure for this sale can be found here. 17.20% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in Acadia Healthcare by 97.2% in the first quarter. Wellington Management Group LLP now owns 6,983,799 shares of the company’s stock valued at $384,877,000 after buying an additional 3,441,579 shares during the last quarter. Geode Capital Management LLC raised its position in Acadia Healthcare by 41.5% in the first quarter. Geode Capital Management LLC now owns 473,045 shares of the company’s stock valued at $26,069,000 after buying an additional 138,635 shares during the last quarter. Loomis Sayles & Co. L P raised its position in Acadia Healthcare by 15.1% in the first quarter. Loomis Sayles & Co. L P now owns 372,070 shares of the company’s stock valued at $20,505,000 after buying an additional 48,864 shares during the last quarter. AXA raised its position in Acadia Healthcare by 11.8% in the first quarter. AXA now owns 94,500 shares of the company’s stock valued at $5,208,000 after buying an additional 10,000 shares during the last quarter. Finally, Park Avenue Institutional Advisers LLC purchased a new position in Acadia Healthcare during the first quarter valued at $471,000.
About Acadia Healthcare
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.
Receive News & Ratings for Acadia Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.